top of page


Targeted LNP Delivery: From GalNAc to Antibody-Guided Next-Generation Nucleic Acid Therapeutics
Introduction: The Next Bottleneck for LNPs Is Not Encapsulation — It’s Precision Lipid nanoparticles (LNPs) have proven their value by enabling the clinical success of mRNA vaccines and multiple nucleic acid therapeutics. However, as therapeutic targets expand beyond the liver to immune cells, the central nervous system, and solid tumors, non-specific biodistribution has emerged as a primary limitation of current LNP platforms . For many LNP-based systems, the key challenge i

Jason Lu
Jan 184 min read
bottom of page
